» Articles » PMID: 32082414

Comparison of Clinical Features and Outcomes Between HBV-related and Non-B Non-C Hepatocellular Carcinoma

Overview
Publisher Biomed Central
Date 2020 Feb 22
PMID 32082414
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the difference between hepatitis B virus related hepatocellular carcinoma (HBV-HCC) and non-HBV non-HCV hepatocellular carcinoma (NBNC-HCC) patients based on clinical features and prognosis.

Methods: A total of 175 patients with HCC were enrolled. Patients' characteristics were extracted from medical records. Among them, 107 patients were positive for HBsAg and negative for HCV-Ab while 68 patients were negative for HBsAg and HCV-Ab.

Results: The patients in the NBNC-HCC group were significantly older than those in the HBV-HCC group ( = 0.045). Moreover, vascular invasion was found in 23.4% of HBV-HCC patients, which was significantly higher than that in the NBNC-HCC patients with 10.3% ( = 0.029). Kaplan-Meier analysis revealed that HBV-HCC patients had significantly worse outcomes in terms of overall survival ( = 0.036). Compared with the NBNC-HCC patients, the HBV-HCC patients had a significantly worse disease-free survival ( = 0.0018). The multivariate analysis results indicated that TNM stage (HR = 1.541, 95%CI 1.072-2.412,  = 0.002) and HBV infection (HR = 1.087, 95%CI 1.012-1.655,  = 0.042) were independent risk variables for overall survival. While vascular invasion (HR = 1.562, 95%CI 1.013-2.815,  = 0.042) and HBV infection (HR = 1.650, 95%CI 1.017-2.676,  = 0.037) were independent risk factors associated with disease-free survival.

Conclusion: Our data revealed that HBV-HCC is more common in young males with vascular invasion, while NBNC-HCC occurs mostly in elderly patients, and overall survival rate is significantly better than that of HBV-HCC. Our study therefore provides evidence that patients with HBV-HCC require closer follow-up due to their poor prognosis.

Citing Articles

Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma.

Ren Z, Shao G, Shen J, Zhang L, Zhu X, Fang W Cancer Immunol Immunother. 2025; 74(2):69.

PMID: 39751879 PMC: 11699032. DOI: 10.1007/s00262-024-03917-w.


Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma.

Chen X, Liu H, Pan D, Yao Z, Han Z, Qu P Technol Cancer Res Treat. 2024; 23:15330338241277695.

PMID: 39263703 PMC: 11406659. DOI: 10.1177/15330338241277695.


Quantitative PCR-based high-sensitivity detection of HBV-DNA levels reflects liver function deterioration in patients with hepatitis B virus-related cirrhosis.

Zhang H, Ding J, Zhou Y Am J Transl Res. 2024; 16(6):2301-2309.

PMID: 39006275 PMC: 11236653. DOI: 10.62347/BDLO2786.


Metabolic self-feeding in HBV-associated hepatocarcinoma centered on feedback between circulation lipids and the cellular MAPK/mTOR axis.

Zhu Y, Zhao Y, Ning Z, Deng Y, Li B, Sun Y Cell Commun Signal. 2024; 22(1):280.

PMID: 38773448 PMC: 11106961. DOI: 10.1186/s12964-024-01619-5.


Prognostic difference between surgery and external radiation in patients with stage I liver cancer based on competitive risk model and conditional survival rate.

Chen R, An Y, Xu M PLoS One. 2024; 19(3):e0298014.

PMID: 38547200 PMC: 10977706. DOI: 10.1371/journal.pone.0298014.


References
1.
Zhang R, Zhou S, Xiao L, Zhang H, Tulahong A, Zhang Y . [Comparison of clinical characteristics of non-B non-C hepatocellular carcinoma and hepatitis virus-related hepatocellular carcinoma and prognosis in Uighur patients]. Zhonghua Zhong Liu Za Zhi. 2015; 37(7):540-4. View

2.
Cai S, Lv F, Zhang Y, Jiang Y, Peng J . Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB. BMC Infect Dis. 2014; 14:85. PMC: 3930760. DOI: 10.1186/1471-2334-14-85. View

3.
Forner A, Reig M, Bruix J . Hepatocellular carcinoma. Lancet. 2018; 391(10127):1301-1314. DOI: 10.1016/S0140-6736(18)30010-2. View

4.
Maini M, Gehring A . The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol. 2016; 64(1 Suppl):S60-S70. DOI: 10.1016/j.jhep.2016.01.028. View

5.
Chan A, Wong G, Chan H, Tong J, Yu Y, Choi P . Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2016; 32(3):667-676. DOI: 10.1111/jgh.13536. View